

许川，男。医学博士，博士后，博士研究生导师，博士后合作导师
电子科技大学医学院附属肿瘤医院/四川省肿瘤医院
肿瘤临床研究中心 主任；兼任整合医学中心筹备组副组长 一病区副主任医师
教授、研究员（教研系列）；副主任医师（医师系列）
电子科技大学博士研究生导师、广西医科大学博士研究生导师
第三军医大学肿瘤学硕士研究生导师、西南医科大学肿瘤学硕士研究生导师
成都中医药大学肿瘤学硕士研究生导师

从事肿瘤综合治疗、个体化与靶向治疗、免疫治疗等临床诊疗及转化医学工作。
研究方向聚焦肿瘤侵袭转移机制、肿瘤细胞异质性与肿瘤免疫微环境重塑。美国
德克萨斯大学 M.D Anderson 癌症中心、维克森林大学医学院肿瘤中心博士后；
法国 Leon Berard 肿瘤医院/国家里昂癌症研究院访问学者。

四川省海内外高层次人才引进 QR 计划“四川省特聘专家”（2018）

重庆市政府“巴渝学者”讲座教授（2019）

四川省杰出青年基金获得者（2020）

电子科技大学青年人才学术托举工程杰出创新人才项目（2020）

国家科学技术进步奖二等奖一项（2019 年，排名第四）

中华医学科技奖一等奖一项（2018 年）

以第一/通讯作者在 *Nature Immunology*、*Advanced Functional Materials*、*The Journal of Clinical Investigation*、*Cancer Research*、*Signal Transduction and Targeted Therapy*、*Bioactive Materials* 等 SCI 期刊发表或接收论文 28 篇，影响因子 ≥ 20 分 1 篇，影响因子 $\geq 10 \leq 20$ 分 6 篇；影响因子 $\geq 5 \leq 10$ 分 11 篇；总被引用 2000 余次。主持国家自然科学基金（4 项）、国家博士后科学基金面上与特别资助（3 项）、国家重点研发计划子课题以及省部级等科研项目 8 项。获得专利授权 4 项（PCT 国际专利 1 项），参编著作 4 部。

学术任职

中国临床肿瘤学会（CSCO）转化医学专委会 常务委员（2020）

中国临床肿瘤学会（CSCO）非小细胞肺癌专委会 委员（2021）

中国临床肿瘤学（CSCO）会患者教育专委会 委员（2020）

中国抗癌协会（CACA）肿瘤支持治疗专委会 委员（2019）

中国抗癌协会（CACA）肿瘤代谢专委会 青年委员（2019）

中国抗癌协会（CACA）肿瘤营养专委会肿瘤免疫营养学组 副组长（2018）

中国抗癌协会（CACA）肿瘤代谢专委会细胞代谢与炎症转化学组 副组长（2019）

中国医药教育协会肺癌医学教育委员会 常务委员（2020）

四川省抗癌协会理事会 理事（2019）

四川省细胞生物学会理事会 理事（2021）

四川省抗癌协会肿瘤精准医学与临床转化专委会 主任委员（2021）

四川省医疗卫生与健康促进会第一届呼吸与危重症专委会 副主任委员 (2021)
四川省抗癌协会肿瘤免疫治疗专业委员会 常务委员 (2020)
四川省抗癌协会第二届抗癌药物专委会 常务委员 (2021)
四川省抗癌协会呼吸病学专委会 常务委员 (2021)
四川省抗癌协会肿瘤标志物专业委员会 委员 (2019)

担任 *Cell Metabolism*、*Advanced Science*、*Advanced Functional Materials*、*Signal Transduct Target Therapy*、*Cancer Letters*、*Frontiers in Immunology* 等期刊审稿人，*Curr Cancer Drug & Targ*、*Frontiers in Molecular Biosciences* 特邀编辑、《中国临床医生杂志》特邀编委、《肿瘤代谢与营养电子杂志》特邀编委。担任国家自然科学基金青年与面上项目评审人。

学术荣誉与奖励

四川省海内外高层次人才 QR 计划引进“四川省特聘专家” (2018)
重庆市政府“巴渝学者”讲座教授 (2019)
四川省杰出青年基金获得者 (2020)
电子科技大学青年人才学术托举工程杰出创新人才项目 (2020)
国家科学技术进步奖二等奖一项 (2019 年，排名第四)
中华医学科技奖一等奖一项 (2018 年)
中华预防医学会科学技术奖一等奖 (2017 年)
美国 Wake Forest Innovations Commercialization Pathway Award (2016)
2021 年勃林格殷格翰-中国创新大赛奖十二强 (2021)

近年代表性论著

通讯作者文章:

- [1] Wu H, Li H, Liu Y, Liang J, Liu Q, Xu Z, Cheng Z, Zhang X, Zhang K, **Xu C**. Blockading a new NSCLC immunosuppressive target by pluripotent autologous tumor vaccines magnifies sequential immunotherapy. **Bioactive Materials**. 2021. doi: 10.1016/j. bioactmat.2021.10.048. **IF: 14.593**
- [2] Shi Y, Wu M, Liu Y, Hu L, Wu H, Xie L, Liu Z, Wu A, Chen L, **Xu C**. ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma. **Frontiers in Oncology**, 2021: 5294. doi.org/10.3389/fonc.2021.769592. **IF:6.244**
- [3] Wu H, Wang T, Liu Y, Li X, Xu S, Wu C, Zou H, Cao M, Jin G, Lang J, Wang B, Liu B, Luo X, **Xu C**. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis. **J Exp Clin Cancer Res**. 2020 Dec 7;39(1):274. doi: 10.1186/ s13046-020-01768-8. PMID: 33280610; PMCID: PMC7720487. **IF:11.161**

- [4] Wang J, Wu H, Song G, Yang D, Huang J, Yao X, Qin H, Chen Z, Xu Z, **Xu C**. A Novel Imidazopyridine Derivative Exerts Anticancer Activity by Inducing Mitochondrial Pathway-Mediated Apoptosis. **Biomed Res Int.** 2020 Aug 25;2020:4929053. doi: 10.1155 /2020/4929053. PMID: 32908894; PMCID: PMC7468608. **IF:3.411**
- [5] Yao Q, Zou L, Lan H, Luo S, Lu S, Lang J, **Xu C**. Initial Experience of a Tele-radiotherapy System for Training Radiation Oncologists in Rural Areas. **J Cancer Educ.** 2020 Jul 28. doi: 10.1007/s13187-020-01836-9. Epub ahead of print. PMID: 32725417. **IF:2.037**
- [6] Zhang K, Li H, Lang J, Li X, Yue W, Yin Y, Du D, Fang Y, Wu H, Zhao Y, **Xu C**. Quantum yield-engineered biocompatible probes illuminate lung tumor based on viscosity confinement-mediated antiaggregation. **Advanced Functional Materials.** 2019. 29(44), 1905124. doi:10.1002/adfm.201905124. **IF:18.808**
- [7] Zou H, Chen Q, Zhang A, Wang S, Wu H, Yuan Y, Wang S, Yu J, Luo M, Wen X, Cui W, Fu W, Yu R, Chen L, Zhang M, Lan H, Zhang X, Xie Q, Jin G, **Xu C**. MPC1 deficiency accelerates lung adenocarcinoma progression through the STAT3 pathway. **Cell Death Dis.** 2019 Feb 15;10(3):148. doi: 10.1038/s41419-019-1324-8. PMID: 30770798; PMCID: PMC6377639. **IF:8.469**
- [8] Zou H, Wang S, Wang S, Wu H, Yu J, Chen Q, Cui W, Yuan Y, Wen X, He J, Chen L, Yu R, Zhang M, Lan H, Jin G, Zhang X, Bian X, **Xu C**. SOX5 interacts with YAP1 to drive malignant potential of non-small cell lung cancer cells. **Am J Cancer Res.** 2018 May 1;8(5):866-878. PMID: 29888108; PMCID: PMC5992510. **IF:6.166**
- [9] Li Y, Lei J, Xu J, Tang DY, Chen ZZ, Zhu J, **Xu C**. A facile method for building fused quinoxaline-quinolinones via an acidless post-Ugi cascade reaction. **Chinese Chemical Letters.** 2017 28(3), 541-545. doi: 10.1016/j.ccllet.2016.10.027. **IF:6.779**

共通通讯文章:

- [1] Liu Y, Wu H, Luo T, Luo Q, Meng Z, Shi Y, Li F, Liu M, Peng X, Liu J, **Xu C**, Tang W. The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer. **Front Mol Biosci.** 2021 May 27;8:646542. doi: 10.3389/fmolb.2021.646542. PMID: 34124145; PMCID: PMC8191464. **IF:5.246**
- [2] Luo Q, He W, Mao T, Leng X, Wu H, Li W, Deng X, Zhao T, Shi M, **Xu C**, Han Y. MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma. **Front Oncol.** 2021 Sep 30;11:711642. doi: 10.3389/fonc.2021.711642. PMID: 34660277; PMCID: PMC8514954. **IF:6.244**

- [3] Zhou J, Zhou F, Chu X, Zhao J, Wu Y, Zhao W, **Xu C**, Su C. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases. **Transl Lung Cancer Res.** 2020 Apr;9(2):316-324. doi: 10.21037/tlcr.2020.04.15. PMID: 32420071; PMCID: PMC7225134. **IF:6.498**
- [4] Yu J, Wu C, Wu Q, Huang J, Fu W, Xie X, Li W, Tang W, **Xu C**, Jin G. PCYT1A suppresses proliferation and migration via inhibiting mTORC1 pathway in lung adenocarcinoma. **Biochem Biophys Res Commun.** 2020 Aug 20;529(2):353-361. doi: 10.1016/j.bbrc.2020.05.164. Epub 2020 Jul 1. PMID: 32703435. **IF:3.575**
- [5] Liu P, Zhu C, Luo J, Lan S, Su D, Wang Q, Wei Z, Cui W, **Xu C**, Yang X. Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3 β signaling pathway activation in glioma. **FASEB J.** 2020 Jan;34(1):1481-1496. doi: 10.1096/fj.201901629RR. Epub 2019 Dec 2. PMID: 31914615. **IF:5.191**
- [6] Xu Z, Ding Y, Meng J, Tang D, Li Y, Lei J, **Xu C**, Chen Z. Facile construction of hydantoin scaffolds via a post-Ugi cascade reaction. **Synlett.** 2018 29(16), 2199-2202. doi: 10.1055/s-0037-1610234. **IF:2.454**
- [7] Wang T, Wu H, Liu S, Lei Z, Qin Z, Wen L, Liu K, Wang X, Guo Y, Liu Q, Liu L, Wang J, Lin L, Mao C, Zhu X, Xiao H, Bian X, Chen D, **Xu C**, Wang B. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance. **Cancer Lett.** 2018 Aug 28;430:11-24. doi: 10.1016/j.canlet.2018.05.003. Epub 2018 May 8. PMID: 29746925. **IF:8.679**
- [8] Xin YH, Bian BS, Yang XJ, Cui W, Cui HJ, Cui YH, Zhang X, **Xu C**, Bian XW. POU5F1 enhances the invasiveness of cancer stem-like cells in lung adenocarcinoma by upregulation of MMP-2 expression. **PLoS One.** 2013 Dec 30;8(12):e83373. doi: 10.1371/journal.pone.0083373. PMID: 24386189; PMCID: PMC3875455. **IF:3.240**

第一作者论著（含共同）：

- [1] Jin G, **Xu C**, Zhang X, Long J, Rezaeian AH, Liu C, Furth ME, Kridel S, Pasche B, Bian XW, Lin HK. Atad3a suppresses Pink1-dependent mitophagy to maintain homeostasis of hematopoietic progenitor cells. **Nat Immunol.** 2018 Jan;19(1):29-40. doi: 10.1038/s41590-017-0002-1. Epub 2017 Nov 21. PMID: 29242539; PMCID: PMC5905408. **IF:25.606**
- [2] **Chuan Xu**, Guoxiang Jin, Hong Wu, Wei Cui, Yuhui Wang, Rajesh Kumar Manne, Guihua Wang, Weina Zhang, Xian Zhang, Fei Han, Zhen Cai, Bo-Syong Pan, Che-Chia Hsu, Yiqiang Liu, Anmei Zhang, Jie Long, Hongbo Zou, Shuang Wang, Xiaodan Ma, Jinling Duan, Bin Wang, Weihui Liu, Haitao Lan, Qing Xiong, Gang Xue, Zhongzhu Chen, Zhigang Xu, Mark E. Furth, Sarah E. Haigh Molin, Yong Lu, Dan Xie, Xiuwu Bian, Hui-Kuan Lin. SIRP γ -expressing cancer

- stem-like cells promote immune escape of lung cancer via Hippo signaling. **The Journal of Clinical Investigation**. 2022 Mar 1; 132(5): e141797. IF:14.808
- [3] Liu WH, Ren LN, Chen T, Liu LY, Jiang JH, Wang T, **Xu C**, Yan HT, Zheng XB, Song FQ, Tang LJ. Abdominal paracentesis drainage ahead of percutaneous catheter drainage benefits patients attacked by acute pancreatitis with fluid collections: a retrospective clinical cohort study. **Crit Care Med**. 2015 Jan;43(1):109-19. doi: 10.1097/CCM.0000000000000606. PMID: 25251762. IF:7.598
- [4] **Xu C**, Xie D, Yu SC, Yang XJ, He LR, Yang J, Ping YF, Wang B, Yang L, Xu SL, Cui W, Wang QL, Fu WJ, Liu Q, Qian C, Cui YH, Rich JN, Kung HF, Zhang X, Bian XW. β -Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. **Cancer Res**. 2013 May 15;73(10): 3181-9. doi: 10.1158/0008-5472.CAN-12-4403. Epub 2013 Mar 28. PMID: 23539445. IF:12.701
- [5] **Xu C**, Chen JA, Qiu Z, Zhao Q, Luo J, Yang L, Zeng H, Huang Y, Zhang L, Cao J, Shu W. Ovotoxicity and PPAR-mediated aromatase downregulation in female Sprague-Dawley rats following combined oral exposure to benzo[a]pyrene and di-(2-ethylhexyl) phthalate. **Toxicol Lett**. 2010 Dec 15;199(3):323-32. doi: 10.1016/j.toxlet.2010.09.015. PMID: 20920559. IF:4.372
- [6] **Xu C**, Zhang JJ, Chen JA, Cao B, Shu WQ, Cao J. Evaluation of ovotoxicity in female mice caused by organic extracts in tap water from Jialing River in Chongqing, China. **Birth Defects Res B Dev Reprod Toxicol**. 2010 Feb;89(1):26-33. doi: 10.1002/bdrb.20219. PMID: 20035550. IF:2.344
- [7] **Xu C**, Shu WQ, Qiu ZQ, Chen JA, Zhao Q, Cao J. Protective effects of green tea polyphenols against subacute hepatotoxicity induced by microcystin-LR in mice. **Environ Toxicol Pharmacol**. 2007 Sep;24(2):140-8. doi: 10.1016/j.etap.2007.04.004. Epub 2007 Apr 21. PMID: 21783802. IF:4.860

通讯作者综述:

- [1] Li W, Li F, Zhang X, Lin H, **Xu C**. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. **Signal Transduct Target Ther**. 2021 Dec 20;6(1):422. doi: 10.1038/s41392-021-00825-8. PMID: 34924561. IF:18.187
- [2] Li Y, Hu L, **Xu C**. Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer. **Curr Opin Oncol**. 2022 Jan 1;34(1):66-76. PMID: 34690284. IF:3.645
- [3] Li W, Peng X, Lang J, **Xu C**. Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer. **Front**

- Pharmacol.** 2020 May 7;11:631. doi: 10.3389/fphar.2020.00631. PMID: 32477121; PMCID: PMC7232544.**IF:5.810**
- [4] Wang D, Wu H, Liang X, Liu J, Li H, **Xu C**. Advances in the Application of Intestinal Flora in Anti-Tumor Therapy. **Journal of Nutritional Oncology.** 2019 4(2). doi: 10.34175/jno2019 02002.
- [5] Qi XW, Zhang F, Wu H, Liu JL, Zong BG, **Xu C**, Jiang J. Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. **Sci Rep.** 2015 Mar 9;5:8924. doi: 10.1038/srep08924. PMID: 25748047; PMCID: PMC4352850.**IF:4.379**
- [6] Wu H, Qi XW, Yan GN, Zhang QB, **Xu C**, Bian XW. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. **PLoS One.** 2014 Jun 18;9(6):e100168. doi: 10.1371/journal.pone.0100168. PMID: 24940615; PMCID: PMC4062503.**IF:3.240**

署名论文（参与工作）：

- [1] Hsu CC, Zhang X, Wang G, Zhang W, Cai Z, Pan BS, Gu H, **Xu C**, Jin G, Xu X, Manne RK, Jin Y, Yan W, Shao J, Chen T, Lin E, Ketkar A, Eoff R, Xu ZG, Chen ZZ, Li HY, Lin HK. Inositol serves as a natural inhibitor of mitochondrial fission by directly targeting AMPK. **Mol Cell.** 2021 Sep 16;81(18):3803-3819.e7. doi: 10.1016/j.molcel.2021.08.025. PMID: 34547240; PMCID: PMC8462099.**IF:17.970**
- [2] Luo J, Lu C, Feng M, Dai L, Wang M, Qiu Y, Zheng H, Liu Y, Li L, Tang B, **Xu C**, Wang Y, Yang X. Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. **J Exp Clin Cancer Res.** 2021 Aug 20;40(1):262. doi: 10.1186/s13046-021-02061-y. PMID: 34416907; PMCID: PMC83779 46. **IF:11.161**
- [3] Hu CS, Huang JH, Yang DL, **Xu C**, Xu ZG, Tan HB, Chen ZZ. Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells. **Oncol Lett.** 2021 Jun;21(6):433. doi: 10.3892/ol.2021.12694. Epub 2021 Mar 31. PMID: 33868471; PMCID: PMC8045161.**IF:2.967**
- [4] Liu M, Wu H, Liu Y, Tan Y, Wang S, Xie S, Xiang R, Liang J, Zhang R, **Xu C**, He J, Li Q. MiR-326 mediates malignant biological behaviors of lung adenocarcinoma by targeting ZEB1. **Sci Prog.** 2021 Apr-Jun;104(2):368504211009379. doi: 10.1177/0036850421100 9379. PMID: 33913391.
- [5] Zou L, Chen X, **Xu C**, Xing L, Xie Y. Design and Preliminary Experience of a Tele-Radiotherapy System for a Medical Alliance in China. **Telemed J E Health.**

- 2020** Feb;26(2):235-243. doi: 10.1089/tmj.2018.0323. Epub 2019 Mar 20. PMID: 30892144.**IF:3.536**
- [6] Zhang W, Wang G, Xu ZG, Tu H, Hu F, Dai J, Chang Y, Chen Y, Lu Y, Zeng H, Cai Z, Han F, **Xu C**, Jin G, Sun L, Pan BS, Lai SW, Hsu CC, Xu J, Chen ZZ, Li HY, Seth P, Hu J, Zhang X, Li H, Lin HK. Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS. **Cell**. **2019** Jun 27;178(1):176-189.e15. doi: 10.1016/j.cell.2019.05.003. Epub 2019 May 30. PMID: 31155231; PMCID: PMC6625351.**IF:41.582**
- [7] Wang G, Long J, Gao Y, Zhang W, Han F, **Xu C**, Sun L, Yang SC, Lan J, Hou Z, Cai Z, Jin G, Hsu CC, Wang YH, Hu J, Chen TY, Li H, Lee MG, Lin HK. SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. **Nat Cell Biol**. **2019** Feb;21(2):214-225. doi: 10.1038/s41556-018-0266-1. Epub 2019 Jan 28. Erratum in: Nat Cell Biol. 2021 Jun;23(6):676. PMID: 30692626; PMCID: PMC6414065.**IF:28.824**
- [8] Pan Y, Gao G, Chen X, Tian Q, Wu F, Liu Q, Wang Y, Jiang T, Liu Y, Li X, Yang S, **Xu C**, Su C, Zhou F, Ren S, Zhou C. Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer. **Thorac Cancer**. **2019** Apr;10(4):686-694. doi: 10.1111/1759-7714.12986. Epub 2019 Feb 22. PMID: 30793872; PMCID: PMC6449243.**IF:3.500**
- [9] Han F, Li CF, Cai Z, Zhang X, Jin G, Zhang WN, **Xu C**, Wang CY, Morrow J, Zhang S, Xu D, Wang G, Lin HK. The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. **Nat Commun**. **2018** Nov 9;9(1):4728. doi: 10.1038/s41467-018-07188-9. PMID: 30413706; PMCID: PMC6226490.**IF:14.919**
- [10] Zhang X, Li CF, Zhang L, Wu CY, Han L, Jin G, Rezaeian AH, Han F, Liu C, **Xu C**, Xu X, Huang CY, Tsai FJ, Tsai CH, Watabe K, Lin HK. TRAF6 Restricts p53 Mitochondrial Translocation, Apoptosis, and Tumor Suppression. **Mol Cell**. **2016** Nov 17;64(4):803-814. doi: 10.1016/j.molcel.2016.10.002. Epub 2016 Nov 3. PMID: 27818144; PMCID: PMC 5541903.**IF:17.970**
- [11] Liao WL, Li SQ, Wang J, Zhang ZY, Yang ZW, Xu D, **Xu C**, Lan HT, Chen ZZ, Xu ZG. An Efficient and Facile Method for the Synthesis of Benzimidazoisoquinoline Derivatives via a Multicomponent Reaction. **ACS Comb Sci**. **2016** Jan 11;18(1):65-9. doi: 10.1021/acscombsci.5b00145. Epub 2015 Dec 18. PMID: 26634875.**IF:3.784**
- [12] Liu WH, Wang T, Yan HT, Chen T, **Xu C**, Ye P, Zhang N, Liu ZC, Tang LJ. Predictors of percutaneous catheter drainage (PCD) after abdominal paracentesis

- drainage (APD) in patients with moderately severe or severe acute pancreatitis along with fluid collections. **PLoS One.** 2015 Feb 6;10(2):e0115348. doi: 10.1371/journal.pone.0115348. PMID: 2565 9143; PMCID: PMC4319763.**IF:3.240**
- [13] Peng L, Bian XW, Li DK, **Xu C**, Wang GM, Xia QY, Xiong Q. Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types. **Sci Rep.** 2015 Aug 21;5:13413. doi: 10.1038/srep13413. PMID: 26 292924; PMCID: PMC4544034.**IF:4.379**
- [14] Wang Z, Wang B, Shi Y, **Xu C**, Xiao HL, Ma LN, Xu SL, Yang L, Wang QL, Dang WQ, Cui W, Yu SC, Ping YF, Cui YH, Kung HF, Qian C, Zhang X, Bian XW. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. **Oncogene.** 2015 Mar 12;34(11):1407-19. doi: 10.1038/onc.2014.75. Epub 2014 Apr 7. PMID: 24704830.**IF:9.867**
- [15] Tang C, Yang L, Jiang X, **Xu C**, Wang M, Wang Q, Zhou Z, Xiang Z, Cui H. Antibiotic drug tigecycline inhibited cell proliferation and induced autophagy in gastric cancer cells. **Biochem Biophys Res Commun.** 2014 Mar 28;446(1):105-12. doi: 10.1016/j.bbrc. 2014.02.043. Epub 2014 Feb 28. PMID: 24582751.**IF:3.575**
- [16] Wang B, Wang Q, Wang Z, Jiang J, Yu SC, Ping YF, Yang J, Xu SL, Ye XZ, **Xu C**, Yang L, Qian C, Wang JM, Cui YH, Zhang X, Bian XW. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. **Cancer Res.** 2014 Oct 15;74(20):5746-57. doi: 10.1158/0008-5472.CAN-13-2563. Epub 2014 Aug 27. PMID: 25164008.**IF:12.701**
- [17] Shi Y, Chen C, Zhang X, Liu Q, Xu JL, Zhang HR, Yao XH, Jiang T, He ZC, Ren Y, Cui W, **Xu C**, Liu L, Cui YH, Yu SZ, Ping YF, Bian XW. Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. **Clin Cancer Res.** 2014 Apr 1;20(7):1803-13. doi: 10.1158/1078-043 2.CCR-13-2284. Epub 2014 Feb 12. PMID: 24523440.**IF:12.531**
- [18] Shan J, Shen J, Liu L, Xia F, **Xu C**, Duan G, Xu Y, Ma Q, Yang Z, Zhang Q, Ma L, Liu J, Xu S, Yan X, Bie P, Cui Y, Bian XW, Qian C. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. **Hepatology.** 2012 Sep;56(3):1004-14. doi: 10.1002/hep.25745. Epub 2012 Jul 12. PMID: 22473773.**IF:17.425**